AdAlta Limited
1AD.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.13M
Close$
Share Statistics
| Market cap | $2.13 Million |
|---|---|
| Enterprise Value | $843,959.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 0.19 |
| Outstanding Shares | 2,975,919,019 |
Return
| Return on Equity | -2481.57% |
|---|---|
| Return on Assets | -533.59% |
| Return on Invested Capital | -2502.30% |
Valuation & Multiples
| P/E Ratio | -1.52 |
|---|---|
| PEG | -9.13 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.25 |
| Enterprise Value to EBIT | -0.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About AdAlta Limited
2 employees
CEO: Timothy Charles Oldham AdAlta Limited is an Australian-based clinical-stage biotechnology company dedicated to the discovery and development of innovative protein therapeutics. Its leading investigational i-body drug candidate, AD-214, is presently in Phase I ...